AI Engines For more Details: Perplexity Kagi Labs You
Bacterial Infections: Cefdinir is effective against a wide range of bacterial infections, including those of the respiratory tract (e.g., pneumonia, bronchitis, sinusitis), skin and soft tissues, urinary tract (e.g., cystitis), and middle ear infections (otitis media).
Mechanism of Action: Cefdinir works by inhibiting bacterial cell wall synthesis, leading to cell wall disruption and bacterial cell death. It achieves this by binding to penicillin-binding proteins (PBPs), similar to other beta-lactam antibiotics.
Spectrum of Activity: Cefdinir has a broad spectrum of activity against Gram-positive bacteria, including Streptococcus pneumoniae and Streptococcus pyogenes, as well as some Gram-negative bacteria like Haemophilus influenzae and Moraxella catarrhalis.
Oral Administration: Cefdinir is typically administered orally, either as capsules or as a suspension. This makes it convenient for outpatient treatment of infections, especially in children who may have difficulty swallowing pills.
Dosage and Duration: The dosage and duration of cefdinir treatment depend on the type and severity of the infection, as well as the patient's age, weight, and renal function. It is important to complete the full course of treatment as prescribed by the healthcare provider to ensure eradication of the infection.
Adverse Effects: Common adverse effects of cefdinir include gastrointestinal symptoms such as diarrhea, nausea, vomiting, and abdominal pain. Skin rash, itching, and allergic reactions may occur, particularly in individuals with a history of penicillin allergy. Anaphylactic reactions are rare but can be severe.
Superinfections: Prolonged or repeated use of cefdinir can lead to the development of superinfections caused by resistant organisms or fungi. Careful monitoring for the emergence of secondary infections is important during treatment.
Drug Interactions: Cefdinir may interact with other medications, including antacids containing aluminum or magnesium, which can reduce its absorption. It is recommended to space the administration of cefdinir and antacids by at least 2 hours.
Renal Impairment: Dosage adjustment may be necessary in patients with renal impairment, as cefdinir is primarily excreted by the kidneys. Accumulation of the drug can occur in patients with impaired renal function, leading to potential toxicity.
Pediatric Use: Cefdinir is commonly used in pediatric patients for the treatment of various bacterial infections. The dosing regimen may need adjustment based on the child's age and weight.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Clostridium beijerinckii | Reduces |
| species | Clostridium butyricum | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.7 | 0.7 | |
| Acne | 0.9 | 0.9 | 0 |
| ADHD | 5.1 | 0.6 | 7.5 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 3.6 | 4 | -0.11 |
| Allergies | 8.3 | 5 | 0.66 |
| Allergy to milk products | 2.7 | 1.6 | 0.69 |
| Alopecia (Hair Loss) | 1.6 | 1.6 | |
| Alzheimer's disease | 7.6 | 8.7 | -0.14 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 4.3 | 1.5 | 1.87 |
| Ankylosing spondylitis | 5.3 | 1.8 | 1.94 |
| Anorexia Nervosa | 1.8 | 3.4 | -0.89 |
| Antiphospholipid syndrome (APS) | 1.9 | 0.3 | 5.33 |
| Asthma | 6.9 | 3.7 | 0.86 |
| Atherosclerosis | 2.7 | 3.2 | -0.19 |
| Atrial fibrillation | 4.1 | 3.4 | 0.21 |
| Autism | 11.3 | 12 | -0.06 |
| Autoimmune Disease | 1.2 | 1.2 | 0 |
| Barrett esophagus cancer | 0.6 | 0.3 | 1 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 3 | 3 | |
| Bipolar Disorder | 2.5 | 1.7 | 0.47 |
| Brain Trauma | 0.9 | 1.4 | -0.56 |
| Breast Cancer | 1.2 | 1.2 | |
| Cancer (General) | 0.9 | 4 | -3.44 |
| Carcinoma | 4.9 | 2.6 | 0.88 |
| Celiac Disease | 3.8 | 4.3 | -0.13 |
| Cerebral Palsy | 2 | 1.3 | 0.54 |
| Chronic Fatigue Syndrome | 6.9 | 8.2 | -0.19 |
| Chronic Kidney Disease | 4.6 | 3.4 | 0.35 |
| Chronic Lyme | 0 | 0.8 | 0 |
| Chronic Obstructive Pulmonary Disease (COPD) | 3 | 2 | 0.5 |
| Chronic Urticaria (Hives) | 2.1 | 1.8 | 0.17 |
| Coagulation / Micro clot triggering bacteria | 1.9 | 1.3 | 0.46 |
| Cognitive Function | 3.6 | 1.8 | 1 |
| Colorectal Cancer | 9.2 | 3.2 | 1.87 |
| Constipation | 2.1 | 0.7 | 2 |
| Coronary artery disease | 3 | 3 | 0 |
| COVID-19 | 12 | 15.4 | -0.28 |
| Crohn's Disease | 10.5 | 6.9 | 0.52 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 1.2 | 1.9 | -0.58 |
| d-lactic acidosis (one form of brain fog) | 0.6 | 0.6 | |
| deep vein thrombosis | 4.2 | 1.4 | 2 |
| Denture Wearers Oral Shifts | 2.1 | 2.1 | |
| Depression | 14 | 12.2 | 0.15 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 2.7 | 3 | -0.11 |
| Endometriosis | 3.5 | 2.6 | 0.35 |
| Eosinophilic Esophagitis | 0.3 | 0.6 | -1 |
| Epilepsy | 4.3 | 2.8 | 0.54 |
| erectile dysfunction | 2.7 | 0.3 | 8 |
| Fibromyalgia | 3.8 | 2.7 | 0.41 |
| Functional constipation / chronic idiopathic constipation | 7.3 | 5 | 0.46 |
| gallstone disease (gsd) | 4.5 | 1.6 | 1.81 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 2.4 | 1.2 | 1 |
| Generalized anxiety disorder | 3.9 | 2.6 | 0.5 |
| giant cell arteritis | 0.3 | 0.4 | -0.33 |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 2.5 | 1.4 | 0.79 |
| Graves' disease | 1.9 | 3.3 | -0.74 |
| Gulf War Syndrome | 1.1 | 2.4 | -1.18 |
| Halitosis | 1.8 | 0.3 | 5 |
| Hashimoto's thyroiditis | 4.4 | 2.3 | 0.91 |
| Heart Failure | 5.1 | 2.4 | 1.13 |
| hemorrhagic stroke | 1.3 | 1.3 | |
| Hidradenitis Suppurativa | 1.4 | 0.3 | 3.67 |
| High Histamine/low DAO | 1.9 | 0.6 | 2.17 |
| hypercholesterolemia (High Cholesterol) | 1.2 | 0.6 | 1 |
| hyperglycemia | 3 | 2.2 | 0.36 |
| Hyperlipidemia (High Blood Fats) | 1.4 | 0.3 | 3.67 |
| hypersomnia | 0.7 | -0.7 | |
| hypertension (High Blood Pressure | 5.8 | 6.6 | -0.14 |
| Hypothyroidism | 0.5 | 1 | -1 |
| Hypoxia | 4.1 | 1.2 | 2.42 |
| IgA nephropathy (IgAN) | 1.9 | 5.4 | -1.84 |
| Inflammatory Bowel Disease | 10.4 | 13 | -0.25 |
| Insomnia | 2.5 | 3.5 | -0.4 |
| Intelligence | 2.1 | 0.6 | 2.5 |
| Intracranial aneurysms | 1.4 | 0.6 | 1.33 |
| Irritable Bowel Syndrome | 10 | 6.8 | 0.47 |
| ischemic stroke | 4 | 2 | 1 |
| Liver Cirrhosis | 9.6 | 6.1 | 0.57 |
| Long COVID | 8.7 | 9.1 | -0.05 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 1.5 | 1.6 | -0.07 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 1.5 | 0.9 | 0.67 |
| ME/CFS with IBS | 1.1 | 2.4 | -1.18 |
| ME/CFS without IBS | 2.4 | 2.4 | 0 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 2.1 | 1.3 | 0.62 |
| Metabolic Syndrome | 9.6 | 10.5 | -0.09 |
| Mood Disorders | 13.8 | 10.2 | 0.35 |
| multiple chemical sensitivity [MCS] | 1.7 | 0.1 | 16 |
| Multiple Sclerosis | 9.3 | 7 | 0.33 |
| Multiple system atrophy (MSA) | 2.3 | 0.7 | 2.29 |
| myasthenia gravis | 0.9 | 1.2 | -0.33 |
| neuropathic pain | 0.3 | 4.1 | -12.67 |
| Neuropathy (all types) | 1.2 | 2.2 | -0.83 |
| neuropsychiatric disorders (PANDAS, PANS) | 1.2 | 1.2 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 6.6 | 5.9 | 0.12 |
| NonCeliac Gluten Sensitivity | 1.9 | 0.6 | 2.17 |
| Obesity | 13 | 11 | 0.18 |
| obsessive-compulsive disorder | 6.4 | 4.8 | 0.33 |
| Osteoarthritis | 3.7 | 1.7 | 1.18 |
| Osteoporosis | 2.7 | 1.9 | 0.42 |
| pancreatic cancer | 1.2 | 0.3 | 3 |
| Parkinson's Disease | 10.3 | 8.4 | 0.23 |
| Polycystic ovary syndrome | 8.3 | 3.9 | 1.13 |
| Postural orthostatic tachycardia syndrome | 0.4 | 0.6 | -0.5 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 1.2 | 2 | -0.67 |
| Primary sclerosing cholangitis | 3.1 | 3.3 | -0.06 |
| Psoriasis | 4.6 | 4 | 0.15 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 9.9 | 5.1 | 0.94 |
| Rosacea | 1.2 | 0.9 | 0.33 |
| Schizophrenia | 7.8 | 3.7 | 1.11 |
| scoliosis | 0.9 | 1.2 | -0.33 |
| Sjögren syndrome | 3.2 | 3.2 | 0 |
| Sleep Apnea | 2.2 | 1.8 | 0.22 |
| Slow gastric motility / Gastroparesis | 1.5 | 0.3 | 4 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 2.4 | 0.6 | 3 |
| Stress / posttraumatic stress disorder | 3.9 | 3.3 | 0.18 |
| Systemic Lupus Erythematosus | 5.3 | 2.4 | 1.21 |
| Tic Disorder | 1.5 | 1.8 | -0.2 |
| Tourette syndrome | 1.4 | 0.3 | 3.67 |
| Type 1 Diabetes | 5.2 | 4.5 | 0.16 |
| Type 2 Diabetes | 10.3 | 9.7 | 0.06 |
| Ulcerative colitis | 7 | 8.7 | -0.24 |
| Unhealthy Ageing | 6.1 | 2.9 | 1.1 |
| Vitiligo | 2.5 | 2.2 | 0.14 |
